Epidemiology;Risk of Infections and Inhibitors in Hemophilia; Chronic lic Synovitis and Long-term Results of Orthopedic Treatment;Laboratory Diagnostics:Coagulation Factors; Inhibitors, Monitoring;Pediatric Hemostaseology;Free Lectures
Epidemiology;Risk of Infections and Inhibitors in Hemophilia; Chronic lic Synovitis and Long-term Results of Orthopedic Treatment;Laboratory Diagnostics:Coagulation Factors; Inhibitors, Monitoring;Pediatric Hemostaseology;Free Lectures
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Motion analysis as introduced 2 years ago on a national basis effectively identifies individual functional disorders and provides a means for describing them on the basis of a score. Individual therapy planning is possible. More treatment tends to produce better function scores and thus helps to lower the strain on the joint. Further study is required in order to determine whether this reduces the incidence of bleeding. Knee function is age-dependent. Height, weight and sporting activity seem to be influencing factors.Demeanor,pain,fatigue and parental motivation do not seem to have an impact.…mehr
Motion analysis as introduced 2 years ago on a national basis effectively identifies individual functional disorders and provides a means for describing them on the basis of a score. Individual therapy planning is possible. More treatment tends to produce better function scores and thus helps to lower the strain on the joint. Further study is required in order to determine whether this reduces the incidence of bleeding. Knee function is age-dependent. Height, weight and sporting activity seem to be influencing factors.Demeanor,pain,fatigue and parental motivation do not seem to have an impact. The roll-and-glide pattern is not age-dependent and probably shows functional abnormalities of the knee.Functional benchmarking of the sites is possible but d- ficult because each site selects the children differently.Age differences also render an overall assessment difficult. Some sites performed negative screening so as to only test children with more severe problems,while other sites performed no such selection.In other sites,the only children to show up for motion analysis were those with well informed parents and who are always involved in all the other activities on offer too.
Epidemiology.- HIV Infection and Causes of Death in Patients with Hemophilia in Germany (Year 2003/2004 Survey).- Hemophilia Registry of the Medical Committee of the Swiss Hemophilia Association — Update and Annual Survey 2004.- Risk of Infections and Inhibitors in Hemophilia.- Update on the Safety of Clotting Factors, Mainly Regarding the Risk of Transmission of vCJD (Variant Creutzfeldt Jakob Disease).- nvCJD and Blood Products in the UK.- Mutation Type Dependent Inhibitor Risk — a Single Center Study on 432 Patients with Severe Hemophilia A.- Inhibitor Incidence in Previously Untreated Patients (PUPs) with Hemophilia A and B. A Prospective Multi-Center Study of the Pediatric Committee of the German, Swiss and Austrian Society for Thrombosis and Hemostasis Research (GTH).- ADVATE Inhibitor Risk Profile: 18 Months post-Licensure.- EACH-Registry: An European Registry for Acquired Hemophilia.- Elective Orthopedic Surgery for Hemophilia Patients with Inhibitors.- Chronic Synovitis and Long-term Results of Orthopedic Treatment.- Results after Total Knee and Hip Replacement in Patients with Hemophilia A — A Single Center Experience.- Motion Analysis Epidemiology in Hemophilic Children.- Radiosynoviorthesis in Hemophilic Arthropathy — A Single Center Experience.- Laboratory Diagnostics: Coagulation Factor, Inhibitors, Monitoring.- Individual Therapy of Hemophilia — New Laboratory Methods Considering Platelets.- Epitope Mapping during FVIII Inhibitor Elimination with Rituximab Reveals Conformational Epitopes on FVIII and Identifies Small Molecules Blocking Inhibitor and Targeting B Cells.- Lack of Factor VIII Expression Represents a Novel Mechanism Leading to Hemophilia A.- Pediatric Hemostaseology.- Effects of the Factor V G1691 A Mutation and the Factor II G20210AVariant on the Clinical Expression of Severe Hemophilia A (< 2%) in Children — Results of a Multicenter Study.- Continuous Infusion of Factor Concentrates in Children with Hemophilia A in Comparison to Bolus Injections.- Decreased Clotting Factor Activity (VIII, IX, XI, and XII) due to Inhibitors with Lupus-like Activity in Childhood.- Free Lectures.- Effect of Activated Recombinant Coagulation Factor VII on the Function of Glycoprotein IIb/IIIa-Inhibited Platelets in Vitro.- Mutation Analysis in Hereditary Angioedema Identifies Patients at Risk for Developing Acute and Life Threatening Edema.- Recurrent Mutation in ADAMTS13 Gene as a Cause of a Hereditary Thrombotic Thrombocytopenic Purpura in the Czech Republic.- Clinical Manifestations of Patients with Dysfibrinogenemia.- Case Report of a FXIII Inhibitor in a 77-year-old Patient.- Poster.- The ABC’s of Hemophilia.- The Long Journey to Being Diagnosed as a Carrier of Hemophilia A — A Woman with Abnormally Prolonged Bleeding after Myocardial Infarction.- Clinical Investigation of Orthopedic Outcome in Patients with Severe Hemophilia — Advantage of an Early Prophylactic Treatment?.- The Relevance of Thrombophilic Risk Factors on Bleeding Tendency in Hemophilia A Patients.- Magnetic Field Therapy in Patients with Severe Hemophilia — Motion Analysis and Quality Control.- The Clinical Course of two Patients Receiving High Dose Factor VIII — Replacement Therapy.- Determination of the Factor VIII Plasma Activity of Hemophilia A Patients Treated with a New Recombinant Factor VIII Concentrate.- Socio-Economic Aspects of Hemophilia Treatment in Romania.- Immunosuppressive Treatment in Acquired von-Willebrand’s Syndrome.- HCV-Infection in HIV-Infected and Non-Infected People with Hemophilia — A RetrospectiveStudy: Medical Aspects.- HCV-Infection in HIV-Infected and Non-Infected People with Hemophilia — A Retrospective Study: Psychosocial Aspects.- Testing Factor VIII Activity by Using the Chromogenic Assay in Carriers of Hemophilia A.- Hip Replacement in Hemophilic Patients — A 30 Years Single Center Experience.- Successful Therapy with anti CD20 Monoclonal Antibody Rituximab in Patients with Acquired Hemophilia against Factor VIII.- Unusual Prolonged Course of an Immune Tolerance Therapy (ITT) in a Patient with Severe Hemophilia A and a High-Titer Inhibitor Development.- Successful Major Surgery with Minimal Dosage of rFVIIa in a Hemophilia A Patient with High Level of Alloantibodies to Factor VIII.- Inhibitor Development after Continuous Infusion of Factor VIII: A Retrospective Study in Germany.- Inhibitors in PTP’S: A Retrospective Study in Germany.- Elective Orthopedic Surgery in Inhibitor Patients — the Frankfurt Concept.- The Frequency of Venous Thromboembolism in Women with FV Leiden in Association with Pregnancy and Puerperium.- Spectrum of Molecular Defects and Mutation Detection Date in Patients with Severe Hemophilia A.- Hemophilia Patients and Prothrombotic Gene Mutation.- ?A1a82Gly Represents a Common Fibrinogen Chain Variant in Caucasians.- A Novel Mutation (Asp36Tyr) in the Vitamin K Epoxide Reductase Complex Subunit 1 Gene (VKORC1) Causes Increased Phenprocoumon Requirement.- Denaturing High Performance Liquid Chromatography Represents an Efficient Technique for Detection of Heterozygous Large Deletions in Antithrombin Gene.- Recurrent Coronary Stent Thrombosis in a Patient with Combined Aspirin and Clopidogrel Resistance.- Coagulation Factor XIII Mutation Profile: Update 2004.- Site-Directed Mutagenesis of VKORC1, the Target Protein ofCoumarin-Type Anticoagulants.- Treatment of Dilution Coagulopathy by Fibrinogen and Platelet Concentrates.- Pathogenesis of Hepatic Veno-Occlusive Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation.
Epidemiology.- HIV Infection and Causes of Death in Patients with Hemophilia in Germany (Year 2003/2004 Survey).- Hemophilia Registry of the Medical Committee of the Swiss Hemophilia Association — Update and Annual Survey 2004.- Risk of Infections and Inhibitors in Hemophilia.- Update on the Safety of Clotting Factors, Mainly Regarding the Risk of Transmission of vCJD (Variant Creutzfeldt Jakob Disease).- nvCJD and Blood Products in the UK.- Mutation Type Dependent Inhibitor Risk — a Single Center Study on 432 Patients with Severe Hemophilia A.- Inhibitor Incidence in Previously Untreated Patients (PUPs) with Hemophilia A and B. A Prospective Multi-Center Study of the Pediatric Committee of the German, Swiss and Austrian Society for Thrombosis and Hemostasis Research (GTH).- ADVATE Inhibitor Risk Profile: 18 Months post-Licensure.- EACH-Registry: An European Registry for Acquired Hemophilia.- Elective Orthopedic Surgery for Hemophilia Patients with Inhibitors.- Chronic Synovitis and Long-term Results of Orthopedic Treatment.- Results after Total Knee and Hip Replacement in Patients with Hemophilia A — A Single Center Experience.- Motion Analysis Epidemiology in Hemophilic Children.- Radiosynoviorthesis in Hemophilic Arthropathy — A Single Center Experience.- Laboratory Diagnostics: Coagulation Factor, Inhibitors, Monitoring.- Individual Therapy of Hemophilia — New Laboratory Methods Considering Platelets.- Epitope Mapping during FVIII Inhibitor Elimination with Rituximab Reveals Conformational Epitopes on FVIII and Identifies Small Molecules Blocking Inhibitor and Targeting B Cells.- Lack of Factor VIII Expression Represents a Novel Mechanism Leading to Hemophilia A.- Pediatric Hemostaseology.- Effects of the Factor V G1691 A Mutation and the Factor II G20210AVariant on the Clinical Expression of Severe Hemophilia A (< 2%) in Children — Results of a Multicenter Study.- Continuous Infusion of Factor Concentrates in Children with Hemophilia A in Comparison to Bolus Injections.- Decreased Clotting Factor Activity (VIII, IX, XI, and XII) due to Inhibitors with Lupus-like Activity in Childhood.- Free Lectures.- Effect of Activated Recombinant Coagulation Factor VII on the Function of Glycoprotein IIb/IIIa-Inhibited Platelets in Vitro.- Mutation Analysis in Hereditary Angioedema Identifies Patients at Risk for Developing Acute and Life Threatening Edema.- Recurrent Mutation in ADAMTS13 Gene as a Cause of a Hereditary Thrombotic Thrombocytopenic Purpura in the Czech Republic.- Clinical Manifestations of Patients with Dysfibrinogenemia.- Case Report of a FXIII Inhibitor in a 77-year-old Patient.- Poster.- The ABC’s of Hemophilia.- The Long Journey to Being Diagnosed as a Carrier of Hemophilia A — A Woman with Abnormally Prolonged Bleeding after Myocardial Infarction.- Clinical Investigation of Orthopedic Outcome in Patients with Severe Hemophilia — Advantage of an Early Prophylactic Treatment?.- The Relevance of Thrombophilic Risk Factors on Bleeding Tendency in Hemophilia A Patients.- Magnetic Field Therapy in Patients with Severe Hemophilia — Motion Analysis and Quality Control.- The Clinical Course of two Patients Receiving High Dose Factor VIII — Replacement Therapy.- Determination of the Factor VIII Plasma Activity of Hemophilia A Patients Treated with a New Recombinant Factor VIII Concentrate.- Socio-Economic Aspects of Hemophilia Treatment in Romania.- Immunosuppressive Treatment in Acquired von-Willebrand’s Syndrome.- HCV-Infection in HIV-Infected and Non-Infected People with Hemophilia — A RetrospectiveStudy: Medical Aspects.- HCV-Infection in HIV-Infected and Non-Infected People with Hemophilia — A Retrospective Study: Psychosocial Aspects.- Testing Factor VIII Activity by Using the Chromogenic Assay in Carriers of Hemophilia A.- Hip Replacement in Hemophilic Patients — A 30 Years Single Center Experience.- Successful Therapy with anti CD20 Monoclonal Antibody Rituximab in Patients with Acquired Hemophilia against Factor VIII.- Unusual Prolonged Course of an Immune Tolerance Therapy (ITT) in a Patient with Severe Hemophilia A and a High-Titer Inhibitor Development.- Successful Major Surgery with Minimal Dosage of rFVIIa in a Hemophilia A Patient with High Level of Alloantibodies to Factor VIII.- Inhibitor Development after Continuous Infusion of Factor VIII: A Retrospective Study in Germany.- Inhibitors in PTP’S: A Retrospective Study in Germany.- Elective Orthopedic Surgery in Inhibitor Patients — the Frankfurt Concept.- The Frequency of Venous Thromboembolism in Women with FV Leiden in Association with Pregnancy and Puerperium.- Spectrum of Molecular Defects and Mutation Detection Date in Patients with Severe Hemophilia A.- Hemophilia Patients and Prothrombotic Gene Mutation.- ?A1a82Gly Represents a Common Fibrinogen Chain Variant in Caucasians.- A Novel Mutation (Asp36Tyr) in the Vitamin K Epoxide Reductase Complex Subunit 1 Gene (VKORC1) Causes Increased Phenprocoumon Requirement.- Denaturing High Performance Liquid Chromatography Represents an Efficient Technique for Detection of Heterozygous Large Deletions in Antithrombin Gene.- Recurrent Coronary Stent Thrombosis in a Patient with Combined Aspirin and Clopidogrel Resistance.- Coagulation Factor XIII Mutation Profile: Update 2004.- Site-Directed Mutagenesis of VKORC1, the Target Protein ofCoumarin-Type Anticoagulants.- Treatment of Dilution Coagulopathy by Fibrinogen and Platelet Concentrates.- Pathogenesis of Hepatic Veno-Occlusive Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497